JP2018535650A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018535650A5 JP2018535650A5 JP2018514962A JP2018514962A JP2018535650A5 JP 2018535650 A5 JP2018535650 A5 JP 2018535650A5 JP 2018514962 A JP2018514962 A JP 2018514962A JP 2018514962 A JP2018514962 A JP 2018514962A JP 2018535650 A5 JP2018535650 A5 JP 2018535650A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- nucleic acid
- hepatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 30
- 102000036639 antigens Human genes 0.000 claims 30
- 108091007433 antigens Proteins 0.000 claims 30
- 239000012634 fragment Substances 0.000 claims 29
- 150000007523 nucleic acids Chemical class 0.000 claims 27
- 108020004707 nucleic acids Proteins 0.000 claims 21
- 102000039446 nucleic acids Human genes 0.000 claims 21
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 208000002672 hepatitis B Diseases 0.000 claims 12
- 108091033319 polynucleotide Proteins 0.000 claims 7
- 102000040430 polynucleotide Human genes 0.000 claims 7
- 239000002157 polynucleotide Substances 0.000 claims 7
- 230000002265 prevention Effects 0.000 claims 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 208000005331 Hepatitis D Diseases 0.000 claims 5
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 3
- 102000014150 Interferons Human genes 0.000 claims 3
- 108010050904 Interferons Proteins 0.000 claims 3
- 229940123066 Polymerase inhibitor Drugs 0.000 claims 3
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 208000000419 Chronic Hepatitis B Diseases 0.000 claims 2
- 241000700721 Hepatitis B virus Species 0.000 claims 2
- 241000724709 Hepatitis delta virus Species 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 208000010471 Chronic Hepatitis D Diseases 0.000 claims 1
- 206010019663 Hepatic failure Diseases 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000001631 haemodialysis Methods 0.000 claims 1
- 230000000322 hemodialysis Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229940047124 interferons Drugs 0.000 claims 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims 1
- 229960001627 lamivudine Drugs 0.000 claims 1
- 231100000835 liver failure Toxicity 0.000 claims 1
- 208000007903 liver failure Diseases 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021068062A JP7171809B2 (ja) | 2015-10-07 | 2021-04-14 | Ｂ型肝炎ウイルスを強力に中和する抗体及びその使用 |
| JP2022175909A JP2023011809A (ja) | 2015-10-07 | 2022-11-02 | Ｂ型肝炎ウイルスを強力に中和する抗体及びその使用 |
| JP2024074160A JP2024097078A (ja) | 2015-10-07 | 2024-05-01 | Ｂ型肝炎ウイルスを強力に中和する抗体及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2015/001970 WO2017059878A1 (en) | 2015-10-07 | 2015-10-07 | Antibodies that potently neutralize hepatitis b virus and uses thereof |
| EPPCT/EP2015/001970 | 2015-10-07 | ||
| PCT/EP2016/074114 WO2017060504A1 (en) | 2015-10-07 | 2016-10-07 | Antibodies that potently neutralize hepatitis b virus and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021068062A Division JP7171809B2 (ja) | 2015-10-07 | 2021-04-14 | Ｂ型肝炎ウイルスを強力に中和する抗体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018535650A JP2018535650A (ja) | 2018-12-06 |
| JP2018535650A5 true JP2018535650A5 (enExample) | 2019-10-31 |
| JP6869968B2 JP6869968B2 (ja) | 2021-05-12 |
Family
ID=54330711
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018514962A Active JP6869968B2 (ja) | 2015-10-07 | 2016-10-07 | Ｂ型肝炎ウイルスを強力に中和する抗体及びその使用 |
| JP2021068062A Active JP7171809B2 (ja) | 2015-10-07 | 2021-04-14 | Ｂ型肝炎ウイルスを強力に中和する抗体及びその使用 |
| JP2022175909A Withdrawn JP2023011809A (ja) | 2015-10-07 | 2022-11-02 | Ｂ型肝炎ウイルスを強力に中和する抗体及びその使用 |
| JP2024074160A Pending JP2024097078A (ja) | 2015-10-07 | 2024-05-01 | Ｂ型肝炎ウイルスを強力に中和する抗体及びその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021068062A Active JP7171809B2 (ja) | 2015-10-07 | 2021-04-14 | Ｂ型肝炎ウイルスを強力に中和する抗体及びその使用 |
| JP2022175909A Withdrawn JP2023011809A (ja) | 2015-10-07 | 2022-11-02 | Ｂ型肝炎ウイルスを強力に中和する抗体及びその使用 |
| JP2024074160A Pending JP2024097078A (ja) | 2015-10-07 | 2024-05-01 | Ｂ型肝炎ウイルスを強力に中和する抗体及びその使用 |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US10683344B2 (enExample) |
| EP (2) | EP3359564B1 (enExample) |
| JP (4) | JP6869968B2 (enExample) |
| KR (1) | KR102725168B1 (enExample) |
| CN (3) | CN114539391A (enExample) |
| AU (1) | AU2016334735B2 (enExample) |
| BR (1) | BR112018002406A2 (enExample) |
| CA (1) | CA2993745A1 (enExample) |
| CY (1) | CY1123462T1 (enExample) |
| DK (1) | DK3359564T3 (enExample) |
| EA (1) | EA038301B1 (enExample) |
| ES (1) | ES2813927T3 (enExample) |
| HR (1) | HRP20201345T1 (enExample) |
| HU (1) | HUE050231T2 (enExample) |
| IL (1) | IL258326B (enExample) |
| LT (1) | LT3359564T (enExample) |
| MX (1) | MX2018004127A (enExample) |
| MY (1) | MY187161A (enExample) |
| PH (1) | PH12018500199A1 (enExample) |
| PL (1) | PL3359564T3 (enExample) |
| PT (1) | PT3359564T (enExample) |
| SI (1) | SI3359564T1 (enExample) |
| WO (2) | WO2017059878A1 (enExample) |
| ZA (1) | ZA201800710B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017059878A1 (en) * | 2015-10-07 | 2017-04-13 | Humabs Biomed Sa | Antibodies that potently neutralize hepatitis b virus and uses thereof |
| EP4389222A3 (en) * | 2018-05-10 | 2024-08-28 | Melbourne Health | Methods and compositions for the treatment of hepatitis b infection |
| CN112770772A (zh) * | 2018-05-16 | 2021-05-07 | 长庚医疗财团法人林口长庚纪念医院 | 新型富亮氨酸重复神经元蛋白1(lrrn1)抗体和其用途 |
| CN112165974B (zh) * | 2018-05-31 | 2024-11-08 | 诺华股份有限公司 | 乙型肝炎抗体 |
| JP7558167B2 (ja) | 2018-12-03 | 2024-09-30 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | オリゴベンズアミド類似体およびがん処置におけるそれらの使用 |
| CN118108836A (zh) * | 2018-12-19 | 2024-05-31 | 胡默波斯生物医学公司 | 中和乙型肝炎病毒的抗体和其用途 |
| CN113543791B (zh) * | 2018-12-20 | 2025-08-05 | 维尔生物科技有限公司 | 组合hbv疗法 |
| KR102084912B1 (ko) * | 2019-01-17 | 2020-03-05 | 주식회사 녹십자 | B형 간염 바이러스 표면 항원의 입체 에피토프 및 이에 특이적으로 결합하는 항체 |
| US12509504B2 (en) | 2019-07-20 | 2025-12-30 | Huahui Health Ltd. | Method of treating HBV infection by using anti-pre-S1 HBV antibodies |
| NZ785788A (en) * | 2019-08-29 | 2025-09-26 | Vir Biotechnology Inc | Antibody compositions and methods for treating hepatitis b virus infection |
| CN113717283B (zh) * | 2020-05-25 | 2023-05-26 | 厦门万泰凯瑞生物技术有限公司 | 一种抗乙型肝炎病毒e抗原的单克隆抗体及其应用 |
| JP7579007B2 (ja) * | 2020-06-02 | 2024-11-07 | 株式会社Rcmg | Ｈｂｖの抗ｒｎａウイルス粒子抗体 |
| BR112022024996A2 (pt) * | 2020-06-08 | 2022-12-27 | Hoffmann La Roche | Anticorpos, ácido nucleico, célula hospedeira, método para produzir um anticorpo, composição farmacêutica, agente terapêutico, uso do anticorpo e método para tratar um indivíduo com hepatite b |
| CN116096383A (zh) * | 2020-06-22 | 2023-05-09 | 杨森制药公司 | 用于治疗丁型肝炎病毒感染的组合物和方法 |
| MX2022015765A (es) * | 2020-06-24 | 2023-03-27 | Vir Biotechnology Inc | Anticuerpos modificados neutralizadores del virus de la hepatitis b y sus usos. |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| EP4284428A1 (en) | 2021-01-26 | 2023-12-06 | VIR Biotechnology, Inc. | Compositions and methods for treating hepatitis b virus infection |
| CN113234144B (zh) * | 2021-05-26 | 2022-02-25 | 武汉工程大学 | 一种人源性抗乙肝表面抗原的单链抗体、制剂、编码基因、载体质粒及宿主细胞 |
| WO2023287352A2 (en) * | 2021-07-15 | 2023-01-19 | National University Of Singapore | Anti-hbv antibodies and uses thereof |
| CN113777312B (zh) * | 2021-09-03 | 2024-02-02 | 普十生物科技(北京)有限公司 | 乙肝抗体片段的制备方法、乙肝抗体片段、试剂盒及应用 |
| WO2023039243A2 (en) * | 2021-09-13 | 2023-03-16 | Achelois Biopharma, Inc. | Hepatitis b virus antivirus (hbv-antivirus) compositions and methods of use |
| US20250101082A1 (en) * | 2021-12-21 | 2025-03-27 | HBVtech, LLC | Methods for eliminating hepatitis b virus cccdna and rcdna and the hepatitis b drugs used in the methods thereof |
| TW202411246A (zh) | 2022-05-23 | 2024-03-16 | 美商維爾生物科技股份有限公司 | 經工程化之b型肝炎病毒中和抗體及其用途 |
| CN116162153B (zh) * | 2022-09-01 | 2024-09-10 | 复旦大学附属中山医院 | 一种乙肝病毒表面抗原的单克隆抗体及其应用 |
| CN118725092B (zh) * | 2023-03-28 | 2025-08-12 | 东莞市朋志生物科技有限公司 | 抗HBs-Ag抗体、检测HBs-Ag的试剂和试剂盒 |
| WO2024249683A2 (en) * | 2023-05-31 | 2024-12-05 | Bluejay Therapeutics, Inc. | Anti-hbsag antibody for treatment of chronic hepatitis d |
| CN119143869A (zh) * | 2023-06-16 | 2024-12-17 | 复旦大学 | 乙肝病毒表面抗体及其应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3766162A (en) | 1971-08-24 | 1973-10-16 | Hoffmann La Roche | Barbituric acid antigens and antibodies specific therefor |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4233402A (en) | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| EP0098110B1 (en) | 1982-06-24 | 1989-10-18 | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD | Long-acting composition |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| WO1997039029A2 (en) | 1996-04-18 | 1997-10-23 | Abbott Laboratories | An antigenic epitope of the a determinant of hepatitis b surface antigen and uses thereof |
| GB9608626D0 (en) * | 1996-04-25 | 1996-07-03 | Univ College Of London | Hepatitis b monoclonal antibodies |
| CA2274585A1 (en) * | 1996-12-30 | 1998-07-09 | Innogenetics N.V. | Annexin v-binding polypeptides derived from hbsag and their uses |
| MY133346A (en) | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
| US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
| AU2004215125B2 (en) | 2003-02-26 | 2011-01-06 | Institute For Research In Biomedicine | Monoclonal antibody production by EBV transformation of B cells |
| US20050163782A1 (en) | 2003-06-27 | 2005-07-28 | Biogen Idec Ma Inc. | Modified binding molecules comprising connecting peptides |
| EP1848740A1 (en) * | 2005-01-14 | 2007-10-31 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, the Department of Health and Human Services, | Monoclonal antibodies that bind or neutralize hepatitis b virus |
| NZ581395A (en) | 2007-05-14 | 2012-08-31 | Biogen Idec Inc | Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto |
| KR20090056537A (ko) * | 2007-11-30 | 2009-06-03 | 주식회사 녹십자 | Ｂ형 간염 바이러스 중화능을 갖는 항체를 유효성분으로포함하는 ｂ형 간염 바이러스 감염의 예방 또는 치료용조성물 |
| NZ592036A (en) | 2008-10-22 | 2012-12-21 | Inst Research In Biomedicine | Methods for producing antibodies from plasma cells |
| AU2013308045B2 (en) * | 2012-08-30 | 2018-10-04 | Replicor Inc. | Methods for the treatment of hepatitis B and hepatitis D infections |
| WO2014072526A1 (en) * | 2012-11-12 | 2014-05-15 | Ruprecht-Karls-Universität Heidelberg | Development of hbv- and/or hdv-susceptible cells, cell lines and non-human animals |
| ES2747760T3 (es) * | 2014-01-16 | 2020-03-11 | Mario Umberto Francesco Mondelli | Neutralización de anticuerpos monoclonales humanos contra el antígeno de superficie del virus de la hepatitis B |
| WO2017059878A1 (en) * | 2015-10-07 | 2017-04-13 | Humabs Biomed Sa | Antibodies that potently neutralize hepatitis b virus and uses thereof |
-
2015
- 2015-10-07 WO PCT/EP2015/001970 patent/WO2017059878A1/en not_active Ceased
-
2016
- 2016-10-07 CN CN202210185497.3A patent/CN114539391A/zh active Pending
- 2016-10-07 LT LTEP16779075.7T patent/LT3359564T/lt unknown
- 2016-10-07 KR KR1020187012979A patent/KR102725168B1/ko active Active
- 2016-10-07 EP EP16779075.7A patent/EP3359564B1/en active Active
- 2016-10-07 DK DK16779075.7T patent/DK3359564T3/da active
- 2016-10-07 BR BR112018002406-6A patent/BR112018002406A2/pt not_active Application Discontinuation
- 2016-10-07 US US15/766,703 patent/US10683344B2/en active Active
- 2016-10-07 HU HUE16779075A patent/HUE050231T2/hu unknown
- 2016-10-07 CN CN202210187026.6A patent/CN114539392B/zh active Active
- 2016-10-07 HR HRP20201345TT patent/HRP20201345T1/hr unknown
- 2016-10-07 EA EA201890874A patent/EA038301B1/ru unknown
- 2016-10-07 MX MX2018004127A patent/MX2018004127A/es unknown
- 2016-10-07 PL PL16779075T patent/PL3359564T3/pl unknown
- 2016-10-07 CA CA2993745A patent/CA2993745A1/en active Pending
- 2016-10-07 ES ES16779075T patent/ES2813927T3/es active Active
- 2016-10-07 EP EP20177206.8A patent/EP3753949A1/en active Pending
- 2016-10-07 WO PCT/EP2016/074114 patent/WO2017060504A1/en not_active Ceased
- 2016-10-07 MY MYPI2018700678A patent/MY187161A/en unknown
- 2016-10-07 PT PT167790757T patent/PT3359564T/pt unknown
- 2016-10-07 CN CN201680055161.8A patent/CN108137675B/zh active Active
- 2016-10-07 SI SI201630896T patent/SI3359564T1/sl unknown
- 2016-10-07 JP JP2018514962A patent/JP6869968B2/ja active Active
- 2016-10-07 AU AU2016334735A patent/AU2016334735B2/en active Active
-
2018
- 2018-01-25 PH PH12018500199A patent/PH12018500199A1/en unknown
- 2018-02-02 ZA ZA2018/00710A patent/ZA201800710B/en unknown
- 2018-03-25 IL IL258326A patent/IL258326B/en unknown
-
2020
- 2020-04-30 US US16/864,087 patent/US11390664B2/en active Active
- 2020-08-26 CY CY20201100795T patent/CY1123462T1/el unknown
-
2021
- 2021-04-14 JP JP2021068062A patent/JP7171809B2/ja active Active
-
2022
- 2022-07-18 US US17/867,466 patent/US12037381B2/en active Active
- 2022-11-02 JP JP2022175909A patent/JP2023011809A/ja not_active Withdrawn
-
2024
- 2024-05-01 JP JP2024074160A patent/JP2024097078A/ja active Pending